Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  oblimersen sodium
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-25 of 32 for your search:
Start Over
Daunorubicin Hydrochloride, Cytarabine and Oblimersen Sodium in Treating Patients With Previously Untreated Acute Myeloid Leukemia
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 60 and over
Sponsor: NCI
Protocol IDs: NCI-2012-02805, CALGB-10201, CDR367323, U10CA031946, NCT00085124
Trial of Dacarbazine With or Without Genasense in Advanced Melanoma
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: AGENDA, GM307, NCT00518895
Olimersen and Irinotecan in Treating Patients With Metastatic or Recurrent Colorectal Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000067529, SACI-IDD-98-32, UTHSC-IDD-98-32, NCI-T98-0094, T98-0094, NCT00004870
Bcl-2 Antisense Oligodeoxynucleotide G3139 and Paclitaxel in Treating Patients With Recurrent Small Cell Lung Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 10117, UCCRC-10017, NCI-T98-0091, T98-0091, NCT00005032
Phase I/II Study of Oblimersen in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: GENTA-GL208, MDA-ID-00337, NCT00021190
Combination Chemotherapy and Oblimersen in Treating Patients With Advanced Colorectal Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000271308, U01CA069853, P30CA054174, SACI-IDD-02-23, NCI-5793, 5793, NCT00055822
Oblimersen in Treating Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-01437, MC0285, MAYO-MC0285, NCI-5826, CDR0000304634, N01CM17104, 5826, NCT00062244
Genasense® (Oblimersen Sodium), Fludarabine, and Rituximab in Subjects With Chronic Lymphocytic Leukemia
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: GL217, NCT00078234
Oblimersen, Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-02600, 12975A, N01CM62201, CDR0000371904, UCCRC-12975A, 6243, NCI-6243, NCT00086944
Carboplatin and Etoposide With or Without Oblimersen Sodium in Treating Patients With Extensive Stage Small Cell Lung Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-02819, CALGB 30103, U10CA031946, NCT00042978
Oblimersen and Doxorubicin in Treating Patients With Advanced Hepatocellular Carcinoma (Liver Cancer)
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000257565, PMH-PHL-011, NCI-5798, 5798, NCT00047229
Oblimersen and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia
Phase: Phase II
Type: Treatment
Status: Completed
Age: 15 and over
Sponsor: NCI
Protocol IDs: NCI-2012-02790, CALGB 10107, U10CA031946, NCT00049192
Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-00617, ID02-148, N01CM17003, N01CM62202, N01CM17107, N01CM62203, MDA-ID-02148, NCI-5808, 5808, NCT00054639
Oblimersen and Interferon Alfa in Treating Patients With Metastatic Renal Cell Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 19 and over
Sponsor: NCI
Protocol IDs: NCI-2012-02828, PHII-42, 5828, N01CM17101, CCC-PHII-42, CHNMC-PHII-42, NCI-5828, NCT00059813
Oblimersen in Treating Patients With Merkel Cell Carcinoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-01446, 03-105, CDR0000354418, NCI-5907, MSKCC-03105, N01CM62207, N01CM62206, 5907, NCT00079131
Docetaxel With or Without Oblimersen in Treating Patients With Hormone-Refractory Adenocarcinoma (Cancer) of the Prostate
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: EORTC-30021, AVENTIS-AVE3139E/2501, NCT00085228
Oblimersen, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000258058, MSGCC-210421, NCI-5824, 5824, NCT00049374
Augmerosen Plus Fludarabine and Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 16 and over
Sponsor: NCI
Protocol IDs: NCI-2012-01399, OSU-99H0257, OSU-9977, NCI-T99-0057, CDR0000067515, T99-0057, NCT00004862
Combination Chemotherapy Plus Oblimersen in Treating Patients With Previously Untreated Extensive-Stage Small Cell Lung Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-02387, 10992A, N01CM17102, CDR0000068667, UCCRC-10992A, NCI-5110, 5110, NCT00017251
Start Over